DAFTAR PUSTAKA

American Association of Diabetes (2021) 'ADA standards of diabetes care 2021', *Diabetes Care*, pp. S21–S226.

American College of Physicians (2018) 'Endocrinology and Metabolism.pdf'. American College of Physicians.

Ackermann, M. *et al.* (2020) 'Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19', *New England Journal of Medicine*, 383(2), pp. 120–128. doi: 10.1056/nejmoa2015432.

Akbari, M. Hassan-Zadeh, V. (2018) 'IL-6 signalling pathways and the development of type 2 diabetes', *Inflammopharmacology*, 26(3), pp. 685–698. doi: 10.1007/s10787-018-0458-0.

Al-kuraishy, H. M. *et al.* (2021) 'COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus', *Frontiers in Cardiovascular Medicine*, 8(May). doi: 10.3389/fcvm.2021.644095.

Asegaonkar, S. B. *et al.* (2011) 'High-sensitivity C-reactive protein: a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile', *Journal of Diabetes and its Complications*, 25(6), pp. 368–370. doi: 10.1016/j.jdiacomp.2011.10.001.

Asghar, A. Sheikh, N. (2017) 'Role of immune cells in obesity induced low grade inflammation and insulin resistance', *Cellular Immunology*, 315(March), pp. 18–26. doi: 10.1016/j.cellimm.2017.03.001.

ATZ labs (2005) 'HK369 Human hsCRP: ELISA kit product information and manual', pp. 1–13.

Bordallo, B. *et al.* (2020) 'Severe COVID-19: What have we learned with the immunopathogenesis?', *Advances in Rheumatology*, 60(1). doi: 10.1186/s42358-020-00151-7.

Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012 Jul 26;367(4):309-18.

Brannick, B., Wynn, A. Dagogo-Jack, S. (2016) 'Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications', *Experimental Biology and Medicine*, 241(12), pp. 1323–1331. doi: 10.1177/1535370216654227.

Burhan, E. *et al.* (2022) *Cedera miokardium pada infeksi COVID-19*, *Pedoman*

tatalaksana COVID-19 edisi 4.

De Candia, P. *et al.* (2019) 'Type 2 diabetes: How much of an autoimmune disease?', *Frontiers in Endocrinology*, 10(JULY). doi: 10.3389/fendo.2019.00451.

Cascella, M. *et al.* (2021) *Features, Evaluation, and Treatment of Coronavirus (COVID-19)*, *StatPearls*.

CDC (2020) *Coronavirus disease 2019 (COVID-19) ultrastructural morphology*.

ChaominWu, MD *et al.* (2020) 'Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China', pp. 1–10. doi: 10.1001/jamainternmed.2020.0994.

Chen, H. *et al.* (2020) 'Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records', *The Lancet*, 395(10226), pp. 809–815. doi: 10.1016/S0140-6736(20)30360-3.

Cheng, Y., Yue, L., Wang, Z., Zhang, J., & Xiang, G. (2021). Hyperglycemia associated with lymphopenia and disease severity of COVID-19 in type 2 diabetes mellitus. *Journal of Diabetes and Its Complications*, *35*(2), 107809. https://doi.org/10.1016/j.jdiacomp.2020.107809

Chen, J. *et al.* (2020) 'Clinical progression of patients with COVID-19 in Shanghai, China', *Journal of Infection*, 80(5), pp. e1–e6. doi: 10.1016/j.jinf.2020.03.004.

Choy, E. Rose-John, S. (2017) 'Interleukin-6 as a multifunctional regulator: Inflammation, immune response, and fibrosis', *Journal of Scleroderma and Related Disorders*, 2(Suppl 2), pp. S1–S5. doi: 10.5301/jsrd.5000265.

Clinical, W. H. O., Who, W. (2020) 'WHO-nCoV-Clinical-2020.3-eng', pp. 1–10.

Coomes, E. A. Haghbayan, H. (2020) 'Interleukin-6 in Covid-19: A systematic review and meta-analysis', *Reviews in Medical Virology*, 30(6), pp. 1–9. doi: 10.1002/rmv.2141.

Drummond, J. B. *et al.* (2018) 'The effect of insulin-induced hypoglycemia on inflammatory markers: A systematic review', *Brain, Behavior, and Immunity*, 73(January), pp. 41–50. doi: 10.1016/j.bbi.2018.05.003.

Drummond, J. B. *et al.* (2021) 'Interleukin-6 response to insulin-induced hypoglycemia is associated with hypothalamic-pituitary-adrenal axis activation', *Journal of Neuroimmunology*, 350(November 2020). doi: 10.1016/j.jneuroim.2020.577446.

Dudley, J. P. Lee, N. T. (2020) 'Disparities in age-specific morbidity and mortality from sars-cov-2 in China and the republic of Korea', *Clinical Infectious Diseases*, 71(15), pp. 863–865. doi: 10.1093/cid/ciaa354.

Dunn, E. Grant, P. (2005) 'Type 2 Diabetes: An Atherothrombotic Syndrome', *Current Molecular Medicine*, 5(3), pp. 323–332. doi: 10.2174/1566524053766059.

Echouffo-Tcheugui, J. B. Selvin, E. (2020) 'Prediabetes and What It Means: The Epidemiological Evidence', *Annual Review of Public Health*, 42, pp. 59–77. doi: 10.1146/annurev-publhealth-090419-102644.

Evans Kreider, K., Pereira, K. Padilla, B. I. (2017) 'Practical Approaches to Diagnosing, Treating and Preventing Hypoglycemia in Diabetes', *Diabetes Therapy*, 8(6), pp. 1427–1435. doi: 10.1007/s13300-017-0325-9.

Feng, X. *et al.* (2020) 'Immune-inflammatory parameters in COVID-19 cases: A systematic review and meta-analysis', *Frontiers in Medicine*, 7(June), pp. 1–14. doi: 10.3389/fmed.2020.00301.

Flavio Tangianu, Para, O. Capello, F. (2021) *COVID-19 in Clinical Practice*. doi: 10.1007/978-3-030-78021-0.

Gao, Y. *et al.* (2020) 'Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19', *Journal of Medical Virology*, 92(7), pp. 791–796. doi: 10.1002/jmv.25770.

Gebhard, C. *et al.* (2020) 'Impact of sex and gender on COVID-19 outcomes in Europe', *Biology of Sex Differences*, 11(1), pp. 1–13. doi: 10.1186/s13293-020-00304-9.

Di Gennaro, F. *et al.* (2020) 'Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review', *International Journal of Environmental Research and Public Health*, 17(8). doi: 10.3390/ijerph17082690.

Grobler, C. *et al.* (2020) 'Covid-19 : The Rollercoaster of Fibrin (Ogen), D-Dimer , Von Willebrand Factor , P-Selectin and Their Interactions with Endothelial Cells , Platelets and Erythrocytes'.

Guan, W. *et al.* (2020) 'Clinical Characteristics of Coronavirus Disease 2019 in China', *New England Journal of Medicine*, 382(18), pp. 1708–1720. doi: 10.1056/NEJMoa2002032.

Grifoni E, et al. Interleukin-6 as prognosticator in patients with COVID-19. J Infect. 2020;81(3):452–82.

Han, M. *et al.* (2021) 'Immunological Characteristics in Type 2 Diabetes Mellitus Among COVID-19 Patients', *Frontiers in Endocrinology*, 12(March), pp. 1–12. doi: 10.3389/fendo.2021.596518.

Han, Y. Yang, H. (2020) 'The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective', *Journal of Medical Virology*, 92(6), pp. 639–644. doi: 10.1002/jmv.25749.

Hariyanto, T. I. *et al.* (2021) 'Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis', *American Journal of Emergency Medicine*, 41(January), pp. 110–119. doi: 10.1016/j.ajem.2020.12.076.

Hellebrekers, P., Vrisekoop, N. Koenderman, L. (2018) 'Neutrophil phenotypes in health and disease', *European Journal of Clinical Investigation*, 48, p. e12943. doi: 10.1111/eci.12943.

Hodgson, K. *et al.* (2015) 'Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections', *Immunology*, 144(2), pp. 171–185. doi: 10.1111/imm.12394.

Hu, B. *et al.* (2014) 'Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma', *Clinical Cancer Research*, 20(23), pp. 6212–6222. doi: 10.1158/1078-0432.CCR-14-0442.

Huang, C. *et al.* (2020) 'Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China', *The Lancet*, 395(10223), pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5.

Jafar, N., Edriss, H. Nugent, K. (2016) 'The effect of short-term hyperglycemia on the innate immune system', *American Journal of the Medical Sciences*, 351(2), pp. 201–211. doi: 10.1016/j.amjms.2015.11.011.

Kenneth McIntosh (2020) 'Coronavirus disease 2019 (COVID-19): Epidemiology, virology, and prevention', *Uptodate*, 1, pp. 1–27.

Khunti, K. *et al.* (2021) 'New-Onset Diabetes', 44(December), pp. 2645–2655.

Klonoff, D. C. *et al.* (2021) 'Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: A multicenter, retrospective hospital-based analysis', *Diabetes Care*, 44(2), pp. 578–585. doi: 10.2337/dc20-1857.

Kucirka, L. M. *et al.* (2020) 'Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure', *Annals of Internal Medicine*, 173(4), pp. 262–267. doi: 10.7326/M20-1495.

Leliefeld, P. H. C., Koenderman, L. Pillay, J. (2015) 'How Neutrophils Shape Adaptive Immune Responses', *Frontiers in Immunology*, 6. doi: 10.3389/fimmu.2015.00471.

Leon-Abarca, J. A. *et al.* (2021) 'Diabetes increases the risk of COVID-19 in an altitude dependent manner: An analysis of 1,280,806 Mexican patients', *PLoS ONE*, 16(8 August), pp. 1–17. doi: 10.1371/journal.pone.0255144.

Letko, M., Marzi, A. Munster, V. (2003) 'Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses', *Nature Microbiology*. doi: 10.1038/s41564-020-0688-y.

Li, Q. *et al.* (2020) 'Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study', *EClinicalMedicine*, 23, p. 100375. doi: 10.1016/j.eclinm.2020.100375.

Lim, S. *et al.* (2021) 'COVID-19 and diabetes mellitus: from pathophysiology to clinical management', *Nature Reviews Endocrinology*, 17(1), pp. 11–30. doi: 10.1038/s41574-020-00435-4.

Liu, Jing *et al.* (2020) 'Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients', *EBioMedicine*, 55, p. 102763. doi: 10.1016/j.ebiom.2020.102763.

Llauradó, G. *et al.* (2012) 'Insulin resistance, low-grade inflammation and type 1 diabetes mellitus', *Acta Diabetologica*, 49(1), pp. 33–39. doi: 10.1007/s00592-011-0257-1.

Lu, Y. *et al.* (2021) 'Clinical characteristics and predictors of mortality in young adults with severe COVID-19: a retrospective observational study', *Annals of Clinical Microbiology and Antimicrobials*, 20(1), p. 3. doi: 10.1186/s12941-020-00412-9.

Luc, K. *et al.* (2019) 'Oxidative stress and inflammatory markers in prediabetes and diabetes', *Journal of Physiology and Pharmacology*, 70(6), pp. 809–824. doi: 10.26402/jpp.2019.6.01.

Maddaloni, E. *et al.* (2020) 'Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: A multicentre retrospective study (CoViDiab II)', *Cardiovascular Diabetology*, 19(1), pp. 1–11. doi: 10.1186/s12933-020-01140-2.

Mahardhika, G. S. (2021) 'Hyperglycemia Induced by COVID-19 with and without Present Diabetes: A Systematic Review', *KELUWIH: Jurnal Kesehatan dan Kedokteran*, 2(2), pp. 64–74. doi: 10.24123/kesdok.v2i2.4431.

Mcgonagle, D. *et al.* (2020) 'The role of cytokines including IL-6 in COVID-19

induced pneumonia and MAS-like disease', *Autoimmunity Reviews*, (January), p. 8. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195002/pdf/main.pdf.

Mechanick, J. I. *et al.* (2018) 'Dysglycemia-based chronic disease: An American association of clinical endocrinologists position statement', *Endocrine Practice*, 24(11), pp. 995–1011. doi: 10.4158/PS-2018-0139.

Med, I. C. *et al.* (2020) 'Pericyte alteration sheds light on micro - vasculopathy in COVID - 19 infection', *Intensive Care Medicine*, pp. 2–3. doi: 10.1007/s00134-020-06147-7.

Michalakis, K. Ilias, I. (2021) 'COVID-19 and hyperglycemia/diabetes', *World Journal of Diabetes*, 12(5), pp. 642–650. doi: 10.4239/wjd.v12.i5.642.

Mirabella, S. *et al.* (2020) 'Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information ', (January).

Moore, J. B. June, C. H. (2020) 'Cytokine release syndrome in severe COVID-19', *Science*, 368(6490), pp. 473–474. doi: 10.1126/science.abb8925.

Mortaz, E. *et al.* (2018) 'Update on Neutrophil Function in Severe Inflammation', *Frontiers in Immunology*, 9. doi: 10.3389/fimmu.2018.02171.

Mozafari, N. *et al.* (2020) 'Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information ', (January).

Nazari, A., Sardoo, A. M. Fard, E. T. (2017) 'Is IL-6 Increased in Type 2 Diabetes Mellitus Patients Independent of Nephropathic Complication?', *Journal of Endocrinology, Diabetes & Obesity*, 5, pp. 10–12. Available at: https://www.jscimedcentral.com/Endocrinology/endocrinology-5-1102.pdf.

O'Brien, M. J. *et al.* (2016) 'Detecting Dysglycemia Using the 2015 United States Preventive Services Task Force Screening Criteria: A Cohort Analysis of Community Health Center Patients', *PLoS Medicine*, 13(7), pp. 1–18. doi: 10.1371/journal.pmed.1002074.

Okabayashi, T. *et al.* (2013) 'Diagnosis and management of insulinoma', *World Journal of Gastroenterology*, 19(6), pp. 829–837. doi: 10.3748/wjg.v19.i6.829.

Ortega, R. *et al.* (2020) 'Personal Protective Equipment and Covid-19', *New England Journal of Medicine*, 382(26), p. e105. doi: 10.1056/nejmvcm2014809.

Pal, R. Bhadada, S. K. (2020) 'Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . COVID 19 and diabetes mellitus: An unholy interaction of two pandemics.', (January).

Park-Wyllie, L. Y. *et al.* (2006) 'Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults', *New England Journal of Medicine*, 354(13), pp. 1352–1361. doi: 10.1056/nejmoa055191.

PDPI *et al.* (2020) *Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020*, *Pedoman Tatalaksana COVID-19*.

Perkeni (2019) 'Pedoman Pengelolaan dan Pencegahaan DM Tipe 2 Dewasa Indonesia', *Perkumpulan Endokrinologi Indonesia*, p. 113. Available at: https://pbperkeni.or.id/wp-content/uploads/2020/07/Pedoman-Pengelolaan-DM-Tipe-2-Dewasa-di-Indonesia-eBook-PDF-1.pdf.

Piarulli, F. *et al.* (2017) 'Low Glucose Concentrations Induce a Similar Inflammatory Response in Monocytes from Type 2 Diabetic Patients and Healthy Subjects', *Oxidative Medicine and Cellular Longevity*, 2017. doi: 10.1155/2017/9185272.

Picchianti Diamanti, A. *et al.* (2020) 'Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity', *International Journal of Molecular Sciences*, 21(9), p. 3330. doi: 10.3390/ijms21093330.

Rehman, K. *et al.* (2017) 'Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus', *Critical Reviews in Eukaryotic Gene Expression*, 27(3), pp. 229–236. doi: 10.1615/CritRevEukaryotGeneExpr.2017019712.

Rehman, K. Akash, M. S. H. (2016) 'Mechanisms of inflammatory responses and development of insulin resistance: How are they interlinked?', *Journal of Biomedical Science*, 23(1), pp. 1–18. doi: 10.1186/s12929-016-0303-y.

Rothan, H. A. Byrareddy, S. N. (2020) 'The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak', *Journal of Autoimmunity*, 109, p. 102433. doi: 10.1016/j.jaut.2020.102433.

Rysz, S. *et al.* (2021) 'Chronic dysglycemia and risk of SARS-CoV-2 associated respiratory failure in hospitalized patients', *Acta Anaesthesiologica Scandinavica*, (September), pp. 1–8. doi: 10.1111/aas.13982.

Saeedi, P. *et al.* (2019) 'Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition', *Diabetes Research and Clinical Practice*, 157, p. 107843. doi: 10.1016/j.diabres.2019.107843.

Sardu, C., Gambardella, J. Morelli, M. B. (2020) 'Hypertension , Thrombosis , Kidney Failure , and Diabetes : Is COVID-19 an Endothelial Disease ? A Comprehensive Evaluation of Clinical and Basic Evidence', (May). doi: 10.3390/jcm9051417.

Satuan Tugas Penanganan COVID-19 (2021) *Peta Sebaran COVID-19*.

Sharma, R. K. *et al.* (2021) 'Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases', *Clinical Science*, 135(1), pp. 1–17. doi: 10.1042/CS20200482.

Shi, Y. *et al.* (2020) 'An overview of COVID-19', 1581, pp. 1–18.

Soelistijo SA, Lindarto D, Decroli E, Permana H, Sucipto KW, Kusnadi Y, et. al (2021) 'Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2021', p. 46.

Susilo, A. *et al.* (2020) 'Coronavirus Disease 2019: Tinjauan Literatur Terkini', *Jurnal Penyakit Dalam Indonesia*, 7(1), p. 45. doi: 10.7454/jpdi.v7i1.415.

Tanaka, T. *et al.* (2014) 'A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy', *Seminars in Immunology*, 26(1), pp. 88–96. doi: 10.1016/j.smim.2014.01.009.

Tanaka, T., Narazaki, M. Kishimoto, T. (2014) 'IL-6 in Inflammation, Immunity, and Disease', *Cold Spring Harbor Perspectives in Biology*, 6(10), pp. a016295–a016295. doi: 10.1101/cshperspect.a016295.

Tanaka, Toshio, Narazaki, M. Kishimoto, T. (2014) 'patterns (DAMPs), which are released from damaged or dying cells in noninfectious inflammations such as burn or trauma, directly or indirectly promote inflammation. During sterile surgical operations, an increase in serum IL66 levels precedes elevation of', 6(Kishimoto 1989), pp. 1–16.

Tanaka, T., Narazaki, M. Kishimoto, T. (2016) 'Immunotherapeutic implications of IL-6 blockade for cytokine storm', *Immunotherapy*, 8(8), pp. 959–970. doi: 10.2217/imt-2016-0020.

Tang, N. *et al.* (2020) 'Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia', *Journal of Thrombosis and Haemostasis*, 18(4), pp. 844–847. doi: 10.1111/jth.14768.

Tate, B., Davis, S. N. (2017) 'in Non-Diabetic Humans', 30(7), pp. 1275–1281.

doi: 10.1016/j.jdiacomp.2016.06.030.Comparative.

Tay, M. Z. *et al.* (2020) 'The trinity of COVID-19: immunity, inflammation and intervention 1,2 ✉'. doi: 10.1038/s41577-020-0311-8.

Tsalamandris, S. *et al.* (2019) 'Risk Factors and Cardiovascular Disease Prevention The Role of Inflammation in Diabetes : Current Concepts and Future Perspectives', pp. 50–59.

Wang, D. *et al.* (2020) 'Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China', *JAMA*, 323(11), p. 1061. doi: 10.1001/jama.2020.1585.

Weng, L.-M., Su, X. Wang, X.-Q. (2021) 'Pain Symptoms in Patients with Coronavirus Disease (COVID-19): A Literature Review', *Journal of Pain Research*, Volume 14, pp. 147–159. doi: 10.2147/JPR.S269206.

WHO (2021) *Coronavirus (COVID-19) Dashboard*.

Wiersinga, W. J. *et al.* (2020) 'Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)', *JAMA*, 324(8), p. 782. doi: 10.1001/jama.2020.12839.

World Health Organization, Mission China Joint (2020) 'Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)', *The WHO-China Joint Mission on Coronavirus Disease 2019*, 2019(February), pp. 16–24.

Yan, Y. *et al.* (2020) 'Clinical characteristics and outcomes of patients with severe covid-19 with diabetes', *BMJ Open Diabetes Research and Care*, 8(1), pp. 1–9. doi: 10.1136/bmjdrc-2020-001343.

Yang, Y., Cai, Z. Zhang, J. (2021) 'Hyperglycemia at admission is a strong predictor of mortality and severe/critical complications in COVID-19 patients: A meta-Analysis', *Bioscience Reports*, 41(2), pp. 1–9. doi: 10.1042/BSR20203584.

Yi, Y. *et al.* (2020) 'COVID-19 : what has been learned and to be learned about the novel coronavirus disease', 16. doi: 10.7150/ijbs.45134.

Zhang, Y. *et al.* (2020) 'Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study', *Diabetes Research and Clinical Practice*, 165, p. 108227. doi: 10.1016/j.diabres.2020.108227.

Zhou, Z., Price, C. C. (2020) 'Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease', *Expert Opinion on Investigational Drugs*, 29(12),

pp. 1407–1412. doi: 10.1080/13543784.2020.1840549.

Zhu, L. *et al.* (2020) 'Association of Blood Glucose Control and Outcomes.pdf', *Cell Metabolism*, 31(June), pp. 1068–1077. Available at: https://pubmed.ncbi.nlm.nih.gov/32369736/.